Skip to content
Open access

Effectiveness of Injectable Semaglutide 1 mg/Week in Hepatic Markers, Fibrosis and Systemic Inflammation in Obese Type 2 Diabetes Patients: A 6-Month Retrospective Real-World Study

Jul 2026 · Endocrines · Vol 7, pp. 39 · 0 citations · 29 references

TL;DR

Six months of injectable semaglutide treatment was associated with favorable metabolic changes and reductions in liver transaminases in patients with type 2 diabetes mellitus, and findings related to FIB-4 and SII should be interpreted cautiously, as these are indirect indices.

Abstract

Background: Type 2 diabetes mellitus is commonly associated with obesity, metabolic liver disease, and chronic low-grade inflammation. Semaglutide is known to improve glycaemic control and body weight, but its real-world associations with hepatic markers, fibrosis-related indices, and systemic inflammatory parameters remain incompletely characterized. This study evaluated changes in metabolic, hepatic, and inflammatory parameters during injectable semaglutide treatment and explored whether these changes differed according to baseline disease status. Methods: A retrospective observational study was conducted in patients with type 2 diabetes treated with injectable semaglutide 1 mg/week and followed for six months. Anthropometric, metabolic, hepatic, and inflammatory variables were collected at baseline and follow-up, including liver enzymes, the Fibrosis-4 (FIB-4) index, and the systemic immune–inflammation (SII) index. Analyses included correlation analyses and exploratory stratification according to baseline fibrosis risk and inflammatory status. Results: Semaglutide treatment was associated with significant reductions in body weight, body mass index, fasting glucose, HbA1c, and triglyceride levels. Alanine and aspartate aminotransferase levels decreased significantly, consistent with a reduction in liver enzyme abnormalities during follow-up. No significant overall changes were observed in FIB-4, an indirect fibrosis-related index, or in SII, an indirect hematological inflammatory index. However, exploratory stratified analyses suggested that patients with higher baseline FIB-4-estimated fibrosis risk or elevated SII values showed greater reductions in these indices, whereas those with low baseline risk showed no relevant changes. Conclusions: In routine clinical practice, six months of injectable semaglutide treatment was associated with favorable metabolic changes and reductions in liver transaminases in patients with type 2 diabetes mellitus. Findings related to FIB-4 and SII should be interpreted cautiously, as these are indirect indices and the baseline-dependent patterns observed were exploratory and hypothesis-generating.

Read PDF

Similar papers

Clinical trial Open access Oct 2026

Efficacy and safety of imeglimin hydrochloride for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes

Preliminary evidence of the potential clinical utility of imeglimin in this population of patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes is provided and warrant confirmation in larger randomized controlled studies.

Hiroki Yamada, Y. Ida, Shiori Kaji et al. · 0 citations
Open access Oct 2026

Effects of imeglimin on liver enzymes and body composition in patients with MASLD and type 2 diabetes: a pilot study

Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM), yet effective pharmacological options remain limited. Imeglimin, a novel antidiabetic agent targeting mitochondrial bioenergetics, has shown potential hepatoprotective effects in precli...

Kaede Fujita, Takanobu Iwadare, Takefumi Kimura et al. · 0 citations
Open access Oct 2026

Serum Interferon Gamma-induced Protein 10 Levels in Patients with Type 2 Diabetes and Metabolic Dysfunction-associated Steatotic Liver Disease: A Case–control Study

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to type 2 diabetes mellitus (T2D), with insulin resistance, dyslipidemia, and inflammation contributing to disease progression. Interferon-γ-inducible protein-10 (IP-10) is a proinflammatory chemokine implicated in hepatic inflammati...

N. Bashir, O. Fawzy, Sara M. Abd Elaziz et al. · 0 citations
Open access Oct 2026

Baseline monocyte SGLT2 mRNA expression and changes in the fibrosis-4 index after luseogliflozin treatment in participants with type 2 diabetes and MASLD

Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in type 2 diabetes. We investigated the association between monocyte mRNA expression of sodium-glucose cotransporter 2 (SGLT2), the molecular target of luseogliflozin, and changes in the fibrosis-4 (FIB-4) index during treatment with this agent....

Hideyuki Okuma · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.